CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 347 enrolled
Drug / intervention
Fingolimod (FTY720)drug
Likely dose
Fingolimod (FTY720) 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01498887
NCT01498887Phase 4Completed
CompareCT.gov

A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.

Novartis Pharmaceuticals·interventional·Posted Dec 26, 2011·Updated Jan 25, 2019

In Brief

A Phase 4 clinical trial evaluating Fingolimod (FTY720) for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 347 participants across 47 sites in 2 countries.

Detailed Summary

This study assessed the efficacy of fingolimod in patients with short duration relapsing-remitting multiple sclerosis who had not been previously treated with disease-modifying therapies (DMTs), versus patients with the same disease duration who had previously received first-line DMTs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Remitting Multiple Sclerosis
CountriesAustralia, Spain
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 26, 2011
Enrollment StartDec 24, 2011
Primary CompletionDec 26, 2015
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 14.5 years ago

Interventions

Fingolimod (FTY720)drug

Hard gelatin capsules containing 0.5 mg of fingolimod.